| Title |
The addition of bevacizumab to standard chemotherapy in breast cancer: which patient benefits the most?
|
|---|---|
| Published in |
SpringerPlus, May 2013
|
| DOI | 10.1186/2193-1801-2-202 |
| Pubmed ID | |
| Authors |
Vibeke Kruse, Hannelore Denys, Rudy Van Den Broecke, Simon Van Belle, Veronique Cocquyt |
| Abstract |
Bevacizumab, a humanized monoclonal antibody directed against vascular endothelial growth factor, is an effective and well-tolerated treatment option for patients with breast cancer. Bevacizumab has demonstrated a gain in progression-free survival and a trend towards an overall survival benefit in various subgroups of breast cancer. Given the lack of a predictive biomarker, we performed a literature search with regard to efficacy and tolerability of bevacizumab in different subgroups of breast cancer patients and in different settings. In the metastatic setting, the efficacy of bevacizumab has been most extensively studied and demonstrated in patients with triple-negative breast cancer, the most difficult-to-treat population among patients with advanced disease and also the group with the biggest need for new treatment options. Overall, bevacizumab is well tolerated with very few serious adverse events. Bevacizumab is also an active and feasible treatment option for patients above 70 years of age. |
Mendeley readers
The data shown below were compiled from readership statistics for 8 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 8 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 3 | 38% |
| Student > Bachelor | 1 | 13% |
| Student > Ph. D. Student | 1 | 13% |
| Professor | 1 | 13% |
| Professor > Associate Professor | 1 | 13% |
| Other | 1 | 13% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 4 | 50% |
| Agricultural and Biological Sciences | 3 | 38% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 13% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 May 2013.
All research outputs
#20,191,579
of 22,708,120 outputs
Outputs from SpringerPlus
#1,461
of 1,852 outputs
Outputs of similar age
#167,837
of 192,823 outputs
Outputs of similar age from SpringerPlus
#59
of 105 outputs
Altmetric has tracked 22,708,120 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,852 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.7. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 192,823 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 105 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.